+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
TauRx Pharmaceuticals Ltd - logo

TauRx Pharmaceuticals Ltd. discovers and develops treatments and diagnostics for Alzheimer's disease and other neurodegenerative diseases. The company's best known product, LMTX, inhibits aggregation of tau, synuclein, TPD-43 and huntingtin proteins. The LMTX Phase 3 clinical trial programme, conducted in over 20 countries and involving over 1,900 patients, has recently completed. TauRx Pharmaceuticals Ltd. was founded in 2002 and is based in Singapore with a research facility in Aberdeen, Scotland.

From
Alzheimer's Disease: Dynamic Market Forecast to 2026 - Product Thumbnail Image

Alzheimer's Disease: Dynamic Market Forecast to 2026

  • Report
  • October 2018
  • 52 Pages
  • Global
From
Alzheimer's Disease: Competitive Landscape to 2026 - Product Thumbnail Image

Alzheimer's Disease: Competitive Landscape to 2026

  • Report
  • June 2018
  • 49 Pages
  • Global
From
Dementia - Pipeline Review, H2 2020 - Product Thumbnail Image

Dementia - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 537 Pages
  • Global
From
Progressive Supranuclear Palsy - Pipeline Review, H1 2020 - Product Thumbnail Image

Progressive Supranuclear Palsy - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 113 Pages
  • Global
From
Tau protein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Tau protein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator